In The Philadelphia Chromosome journalist Jessica Wapner tells the story of the breakthrough cancer drug Gleevec, which has saved the lives of thousands of patients with chronic myeloid leukemia (CML) and other cancers since the U.S. Food and Drug Administration approved it in 2001. It was the first targeted cancer drug, developed after researchers identified the genetic mutation that gave rise to CML, and it set in motion the race to uncover the genetic roots of a wide range of cancers.
[More]
